Drug intelligence / Profile preview

MKK900

Development stage: Phase 1
Lead developer: MAXVAX Biotechnology
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MKK900 is a recombinant, stabilized pre-fusion F (pre-F) protein subunit vaccine developed by MAXVAX Biotechnology for the prevention of respiratory syncytial virus (RSV) infection. The vaccine is designed to elicit a potent immune response by presenting the RSV fusion protein in its highly immunogenic pre-fusion conformation, which is the primary target for neutralizing antibodies. MKK900 is formulated without an adjuvant and is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and immunogenicity in healthy women aged 18 to 49 years, with a potential application in maternal immunization to protect infants from RSV-related disease.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on MKK900.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MKK900.

Explore the full profile